

# Theodore R Levin

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2798082/publications.pdf>

Version: 2024-02-01

113  
papers

21,920  
citations

28190

55  
h-index

23472

111  
g-index

118  
all docs

118  
docs citations

118  
times ranked

15519  
citing authors

#	ARTICLE	IF	CITATIONS
1	Colorectal cancer screening and surveillance: Clinical guidelines and rationale? Update based on new evidence. <i>Gastroenterology</i> , 2003, 124, 544-560.	0.6	2,016
2	Screening and Surveillance for the Early Detection of Colorectal Cancer and Adenomatous Polyps, 2008: A Joint Guideline From the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. <i>Gastroenterology</i> , 2008, 134, 1570-1595.	0.6	2,002
3	Guidelines for Colonoscopy Surveillance After Screening and Polypectomy: A Consensus Update by the US Multi-Society Task Force on Colorectal Cancer. <i>Gastroenterology</i> , 2012, 143, 844-857.	0.6	1,717
4	Adenoma Detection Rate and Risk of Colorectal Cancer and Death. <i>New England Journal of Medicine</i> , 2014, 370, 1298-1306.	13.9	1,653
5	Screening and Surveillance for the Early Detection of Colorectal Cancer and Adenomatous Polyps, 2008: A Joint Guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. <i>Ca-A Cancer Journal for Clinicians</i> , 2008, 58, 130-160.	157.7	1,491
6	Multitarget Stool DNA Testing for Colorectal-Cancer Screening. <i>New England Journal of Medicine</i> , 2014, 370, 1287-1297.	13.9	1,352
7	Quality in the technical performance of colonoscopy and the continuous quality improvement process for colonoscopy: recommendations of the U.S. Multi-Society Task Force on Colorectal Cancer. <i>American Journal of Gastroenterology</i> , 2002, 97, 1296-1308.	0.2	961
8	Poor Survival Associated with the BRAF V600E Mutation in Microsatellite-Stable Colon Cancers. <i>Cancer Research</i> , 2005, 65, 6063-6069.	0.4	701
9	Accuracy of Fecal Immunochemical Tests for Colorectal Cancer. <i>Annals of Internal Medicine</i> , 2014, 160, 171-181.	2.0	528
10	Colorectal Cancer Screening: Recommendations for Physicians and Patients From the U.S. Multi-Society Task Force on Colorectal Cancer. <i>Gastroenterology</i> , 2017, 153, 307-323.	0.6	512
11	Complications of Colonoscopy in an Integrated Health Care Delivery System. <i>Annals of Internal Medicine</i> , 2006, 145, 880.	2.0	489
12	Colorectal Cancer Screening: Recommendations for Physicians and Patients from the U.S. Multi-Society Task Force on Colorectal Cancer. <i>American Journal of Gastroenterology</i> , 2017, 112, 1016-1030.	0.2	483
13	Guidelines on Genetic Evaluation and Management of Lynch Syndrome: A Consensus Statement by the US Multi-Society Task Force on Colorectal Cancer. <i>Gastroenterology</i> , 2014, 147, 502-526.	0.6	397
14	Guidelines on Genetic Evaluation and Management of Lynch Syndrome: A Consensus Statement by the US Multi-Society Task Force on Colorectal Cancer. <i>American Journal of Gastroenterology</i> , 2014, 109, 1159-1179.	0.2	363
15	Screening for Colorectal Neoplasms With New Fecal Occult Blood Tests: Update on Performance Characteristics. <i>Journal of the National Cancer Institute</i> , 2007, 99, 1462-1470.	3.0	346
16	Effects of Organized Colorectal Cancer Screening on Cancer Incidence and Mortality in a Large Community-Based Population. <i>Gastroenterology</i> , 2018, 155, 1383-1391.e5.	0.6	329
17	Optimizing Adequacy of Bowel Cleansing for Colonoscopy: Recommendations From the US Multi-Society Task Force on Colorectal Cancer. <i>Gastroenterology</i> , 2014, 147, 903-924.	0.6	322
18	Incidence and Mortality of Colorectal Adenocarcinoma in Persons With Inflammatory Bowel Disease From 1998 to 2010. <i>Gastroenterology</i> , 2012, 143, 382-389.	0.6	273

#	ARTICLE	IF	CITATIONS
19	Recommendations on Fecal Immunochemical Testing to Screen for Colorectal Neoplasia: A Consensus Statement by the US Multi-Society Task Force on Colorectal Cancer. <i>Gastroenterology</i> , 2017, 152, 1217-1237.e3.	0.6	268
20	Effectiveness of screening colonoscopy in reducing the risk of death from right and left colon cancer: a large community-based study. <i>Gut</i> , 2018, 67, 291-298.	6.1	264
21	Standardized colonoscopy reporting and data system: report of the Quality Assurance Task Group of the National Colorectal Cancer Roundtable. <i>Gastrointestinal Endoscopy</i> , 2007, 65, 757-766.	0.5	258
22	Stool DNA and Occult Blood Testing for Screen Detection of Colorectal Neoplasia. <i>Annals of Internal Medicine</i> , 2008, 149, 441.	2.0	244
23	Association Between Time to Colonoscopy After a Positive Fecal Test Result and Risk of Colorectal Cancer and Cancer Stage at Diagnosis. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 1631.	3.8	198
24	Variation of Adenoma Prevalence by Age, Sex, Race, and Colon Location in a Large Population: Implications for Screening and Quality Programs. <i>Clinical Gastroenterology and Hepatology</i> , 2013, 11, 172-180.	2.4	197
25	Fecal Immunochemical Test Program Performance Over 4 Rounds of Annual Screening. <i>Annals of Internal Medicine</i> , 2016, 164, 456.	2.0	186
26	Public health impact of achieving 80% colorectal cancer screening rates in the United States by 2018. <i>Cancer</i> , 2015, 121, 2281-2285.	2.0	180
27	Diet and lifestyle factor associations with CpG island methylator phenotype and BRAF mutations in colon cancer. <i>International Journal of Cancer</i> , 2007, 120, 656-663.	2.3	177
28	Shifts in the Fecal Microbiota Associated with Adenomatous Polyps. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2017, 26, 85-94.	1.1	168
29	Predicting Advanced Proximal Colonic Neoplasia With Screening Sigmoidoscopy. <i>JAMA - Journal of the American Medical Association</i> , 1999, 281, 1611.	3.8	163
30	Organized Colorectal Cancer Screening in Integrated Health Care Systems. <i>Epidemiologic Reviews</i> , 2011, 33, 101-110.	1.3	163
31	Colonoscopy Surveillance After Colorectal Cancer Resection: Recommendations of the US Multi-Society Task Force on Colorectal Cancer. <i>Gastroenterology</i> , 2016, 150, 758-768.e11.	0.6	151
32	Colorectal cancer screening: Recommendations for physicians and patients from the U.S. Multi-Society Task Force on Colorectal Cancer. <i>Gastrointestinal Endoscopy</i> , 2017, 86, 18-33.	0.5	145
33	Screening Colonoscopy and Risk for Incident Late-Stage Colorectal Cancer Diagnosis in Average-Risk Adults. <i>Annals of Internal Medicine</i> , 2013, 158, 312.	2.0	142
34	Optimizing Adequacy of Bowel Cleansing for Colonoscopy: Recommendations From the US Multi-Society Task Force on Colorectal Cancer. <i>American Journal of Gastroenterology</i> , 2014, 109, 1528-1545.	0.2	119
35	Optimizing adequacy of bowel cleansing for colonoscopy: recommendations from the U.S. Multi-Society Task Force on Colorectal Cancer. <i>Gastrointestinal Endoscopy</i> , 2014, 80, 543-562.	0.5	106
36	Time to Colonoscopy after Positive Fecal Blood Test in Four U.S. Health Care Systems. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016, 25, 344-350.	1.1	106

#	ARTICLE	IF	CITATIONS
37	Work loss costs due to peptic ulcer disease and gastroesophageal reflux disease in a Health Maintenance Organization. <i>American Journal of Gastroenterology</i> , 2000, 95, 788-792.	0.2	104
38	Complications of screening flexible sigmoidoscopy. <i>Gastroenterology</i> , 2002, 123, 1786-1792.	0.6	103
39	Costs of Acid-Related Disorders to a Health Maintenance Organization. <i>American Journal of Medicine</i> , 1997, 103, 520-528.	0.6	102
40	Colorectal cancer deaths attributable to nonuse of screening in the United States. <i>Annals of Epidemiology</i> , 2015, 25, 208-213.e1.	0.9	102
41	Current and future colorectal cancer screening strategies. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2022, 19, 521-531.	8.2	102
42	Genetic polymorphisms in one-carbon metabolism: associations with CpG island methylator phenotype (CIMP) in colon cancer and the modifying effects of diet. <i>Carcinogenesis</i> , 2007, 28, 1672-1679.	1.3	93
43	Interventions to Improve Follow-up of Positive Results on Fecal Blood Tests. <i>Annals of Internal Medicine</i> , 2017, 167, 565.	2.0	91
44	Long-term Risk of Colorectal Cancer and Related Death After Adenoma Removal in a Large, Community-based Population. <i>Gastroenterology</i> , 2020, 158, 884-894.e5.	0.6	85
45	Omeprazole Improves Peak Expiratory Flow Rate and Quality of Life in Asthmatics With Gastroesophageal Reflux. <i>American Journal of Gastroenterology</i> , 1998, 93, 1060-1063.	0.2	84
46	Dietary Antioxidants, Fruits, and Vegetables and the Risk of Barrett's Esophagus. <i>American Journal of Gastroenterology</i> , 2008, 103, 1614-1623.	0.2	80
47	Modifiable Failures in the Colorectal Cancer Screening Process and Their Association With Risk of Death. <i>Gastroenterology</i> , 2019, 156, 63-74.e6.	0.6	78
48	Change in Body Size and the Risk of Colorectal Adenomas. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2007, 16, 526-531.	1.1	77
49	Mailed fecal immunochemical test outreach for colorectal cancer screening: Summary of a Centers for Disease Control and Prevention-sponsored Summit. <i>Ca-A Cancer Journal for Clinicians</i> , 2020, 70, 283-298.	157.7	75
50	Diagnosis, Comorbidities, and Management of Irritable Bowel Syndrome in Patients in a Large Health Maintenance Organization. <i>Clinical Gastroenterology and Hepatology</i> , 2012, 10, 37-45.	2.4	72
51	Variation in Adenoma Detection Rate and the Lifetime Benefits and Cost of Colorectal Cancer Screening. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 2349.	3.8	72
52	The Colorectal Cancer Screening Process in Community Settings: A Conceptual Model for the Population-Based Research Optimizing Screening through Personalized Regimens Consortium. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 1147-1158.	1.1	64
53	Associations between apoE genotype and colon and rectal cancer. <i>Carcinogenesis</i> , 2005, 26, 1422-1429.	1.3	61
54	Colonoscopy Surveillance after Colorectal Cancer Resection: Recommendations of the US Multi-Society Task Force on Colorectal Cancer. <i>American Journal of Gastroenterology</i> , 2016, 111, 337-346.	0.2	59

#	ARTICLE	IF	CITATIONS
55	Screening in liver disease: Report of an AASLD clinical workshop. <i>Hepatology</i> , 2004, 39, 1204-1212.	3.6	57
56	Long-term Risk of Colorectal Cancer and Related Deaths After a Colonoscopy With Normal Findings. <i>JAMA Internal Medicine</i> , 2019, 179, 153.	2.6	57
57	A Comparison of Fecal Immunochemical and High-Sensitivity Guaiac Tests for Colorectal Cancer Screening. <i>American Journal of Gastroenterology</i> , 2017, 112, 1728-1735.	0.2	56
58	Recommendations on Fecal Immunochemical Testing to Screen for Colorectal Neoplasia: A Consensus Statement by the US Multi-Society Task Force on Colorectal Cancer. <i>American Journal of Gastroenterology</i> , 2017, 112, 37-53.	0.2	56
59	Recommendations on fecal immunochemical testing to screen for colorectal neoplasia: a consensus statement by the US Multi-Society Task Force on colorectal cancer. <i>Gastrointestinal Endoscopy</i> , 2017, 85, 2-21.e3.	0.5	55
60	Quality in the technical performance of screening flexible sigmoidoscopy: recommendations of an international multi-society task group. <i>Gut</i> , 2005, 54, 807-813.	6.1	51
61	Race/Ethnicity and Adoption of a Population Health Management Approach to Colorectal Cancer Screening in a Community-Based Healthcare System. <i>Journal of General Internal Medicine</i> , 2016, 31, 1323-1330.	1.3	50
62	Quality of Life Measurement Clarifies The Cost-Effectiveness of Helicobacter Pylori Eradication in Peptic Ulcer Disease and Uninvestigated Dyspepsia. <i>American Journal of Gastroenterology</i> , 2001, 96, 338-347.	0.2	48
63	Influence of Varying Quantitative Fecal Immunochemical Test Positivity Thresholds on Colorectal Cancer Detection. <i>Annals of Internal Medicine</i> , 2018, 169, 439-447.	2.0	47
64	Interactions Between CYP2C9 and UGT1A6 Polymorphisms and Nonsteroidal Anti-Inflammatory Drugs in Colorectal Cancer Prevention. <i>Clinical Gastroenterology and Hepatology</i> , 2006, 4, 894-901.	2.4	46
65	PPAR $\beta$ and Colon and Rectal Cancer: Associations with Specific Tumor Mutations, Aspirin, Ibuprofen and Insulin-Related Genes (United States). <i>Cancer Causes and Control</i> , 2006, 17, 239-249.	0.8	44
66	Health Benefits and Cost-effectiveness of a Hybrid Screening Strategy for Colorectal Cancer. <i>Clinical Gastroenterology and Hepatology</i> , 2013, 11, 1158-1166.	2.4	40
67	Hepatic Effects of Lovastatin Exposure in Patients with Liver Disease. <i>Drug Safety</i> , 2008, 31, 325-334.	1.4	31
68	Diagnosis and predictors of sessile serrated adenoma after educational training in a large, community-based, integrated healthcare setting. <i>Gastrointestinal Endoscopy</i> , 2018, 87, 755-765.e1.	0.5	28
69	Association between Improved Colorectal Screening and Racial Disparities. <i>New England Journal of Medicine</i> , 2022, 386, 796-798.	13.9	28
70	Strategies to Improve Follow-up After Positive Fecal Immunochemical Tests in a Community-Based Setting: A Mixed-Methods Study. <i>Clinical and Translational Gastroenterology</i> , 2019, 10, e00010.	1.3	27
71	Increased Risk of Colorectal Cancer in Individuals With a History of Serrated Polyps. <i>Gastroenterology</i> , 2020, 159, 502-511.e2.	0.6	27
72	Development and validation of an algorithm for classifying colonoscopy indication. <i>Gastrointestinal Endoscopy</i> , 2015, 81, 575-582.e4.	0.5	26

#	ARTICLE	IF	CITATIONS
73	Automated phone and mail population outreach to promote colorectal cancer screening. <i>American Journal of Managed Care</i> , 2012, 18, 370-8.	0.8	26
74	Effectiveness and Reach of the FLU-FIT Program in an Integrated Health Care System: A Multisite Randomized Trial. <i>American Journal of Public Health</i> , 2013, 103, 1128-1133.	1.5	25
75	Fecal Immunochemical Test (FIT) for Colon Cancer Screening: Variable Performance with Ambient Temperature. <i>Journal of the American Board of Family Medicine</i> , 2016, 29, 672-681.	0.8	24
76	Accurate Identification of Colonoscopy Quality and Polyp Findings Using Natural Language Processing. <i>Journal of Clinical Gastroenterology</i> , 2019, 53, e25-e30.	1.1	24
77	Program Components and Results From an Organized Colorectal Cancer Screening Program Using Annual Fecal Immunochemical Testing. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 145-152.	2.4	21
78	Improved Marker Combination for Detection of De Novo Genetic Variation and Aberrant DNA in Colorectal Neoplasia. <i>Clinical Chemistry</i> , 2006, 52, 2299-2302.	1.5	20
79	Colonoscopy surveillance after colorectal cancer resection: recommendations of the US multi-society task force on colorectal cancer. <i>Gastrointestinal Endoscopy</i> , 2016, 83, 489-498.e10.	0.5	20
80	The Road Ahead: What if Gastroenterologists Were Accountable for Preventing Colorectal Cancer?. <i>Clinical Gastroenterology and Hepatology</i> , 2013, 11, 204-207.	2.4	18
81	Early Screening of African Americans (45-50 Years Old) in a Fecal Immunochemical Test-Based Colorectal Cancer Screening Program. <i>Gastroenterology</i> , 2020, 159, 1695-1704.e1.	0.6	18
82	Impact of the COVID-19 Pandemic on Fecal Immunochemical Testing, Colonoscopy Services, and Colorectal Neoplasia Detection in a Large United States Community-based Population. <i>Gastroenterology</i> , 2022, 163, 723-731.e6.	0.6	18
83	Cimetidine Use and Risk of Breast, Prostate, and Other Cancers. , 2000, 9, 149-155.		17
84	Optimizing Colorectal Cancer Screening by Getting FIT Right. <i>Gastroenterology</i> , 2011, 141, 1551-1555.	0.6	17
85	Lack of significant association between serum inflammatory cytokine profiles and the presence of colorectal adenoma. <i>BMC Cancer</i> , 2015, 15, 123.	1.1	17
86	Flexible Sigmoidoscopy. <i>Gastrointestinal Endoscopy Clinics of North America</i> , 2002, 12, 23-40.	0.6	15
87	Performance of a quantitative fecal immunochemical test for detecting advanced colorectal neoplasia: a prospective cohort study. <i>BMC Cancer</i> , 2018, 18, 509.	1.1	15
88	What Is Organized Screening and What Is Its Value?. <i>Gastrointestinal Endoscopy Clinics of North America</i> , 2020, 30, 393-411.	0.6	15
89	Validation of an Algorithm to Identify Patients at Risk for Colorectal Cancer Based on Laboratory Test and Demographic Data in Diverse, Community-Based Population. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2734-2741.e6.	2.4	14
90	Risk stratification for colorectal cancer in individuals with subtypes of serrated polyps. <i>Gut</i> , 2022, 71, 2022-2029.	6.1	14

#	ARTICLE	IF	CITATIONS
91	Colorectal Cancer Screening Initiation After Age 50 Years in an Organized Program. American Journal of Preventive Medicine, 2017, 53, 335-344.	1.6	13
92	Implications of New Colorectal Cancer Screening Technologies for Primary Care Practice. Medical Care, 2008, 46, S138-S146.	1.1	12
93	Genetic Biomarker Prevalence Is Similar in Fecal Immunochemical Test Positive and Negative Colorectal Cancer Tissue. Digestive Diseases and Sciences, 2017, 62, 678-688.	1.1	12
94	Flexible sigmoidoscopy for colorectal cancer screening: valid approach or short-sighted?. Gastroenterology Clinics of North America, 2002, 31, 1015-1029.	1.0	9
95	Dealing With Uncertainty: Surveillance Colonoscopy After Polypectomy. American Journal of Gastroenterology, 2007, 102, 1745-1747.	0.2	9
96	Colorectal cancer screening: 80% by 2018. Colonoscopists simply cannot do it alone. Gastrointestinal Endoscopy, 2016, 83, 552-554.	0.5	9
97	Disparities in Preventable Mortality from Colorectal Cancer: Are They the Result of Structural Racism?. Gastroenterology, 2021, 160, 1022-1025.	0.6	9
98	Re: Risk of Perforation After Colonoscopy and Sigmoidoscopy: A Population-Based Study. Journal of the National Cancer Institute, 2003, 95, 830-831.	3.0	7
99	In Screening for Colorectal Cancer, Is the FIT Right for the Right Side of the Colon?. Annals of Internal Medicine, 2018, 169, 650.	2.0	7
100	The Importance of Choosing Colorectal Cancer Screening Tests. Archives of Internal Medicine, 2012, 172, 582.	4.3	6
101	Colorectal Cancer Screening Participation Among Asian Americans Overall and Subgroups in an Integrated Health Care Setting with Organized Screening. Clinical and Translational Gastroenterology, 2018, 9, e186.	1.3	6
102	CDC Grand Rounds: the future of cancer screening. Morbidity and Mortality Weekly Report, 2015, 64, 324-7.	9.0	5
103	Prevention of colorectal cancer through multiomics blood testing: The PREEMPT CRC study.. Journal of Clinical Oncology, 2022, 40, TPS208-TPS208.	0.8	5
104	Editorial: Taking FIT to the People: Out of the Office and Into the Mail. American Journal of Gastroenterology, 2012, 107, 108-110.	0.2	4
105	Colorectal Cancer Screening: Money Isn't Everything . . . But It Helps!. Gastroenterology, 2017, 153, 1181-1183.	0.6	4
106	Balancing Adherence and Expense: The Cost-Effectiveness of Two-Sample vs One-Sample Fecal Immunochemical Test. Population Health Management, 2019, 22, 83-89.	0.8	4
107	Ten-year incidence of colorectal cancer following a negative screening sigmoidoscopy: an update from the Colorectal Cancer Prevention (CoCaP) programme. Gut, 2016, 65, 271-277.	6.1	3
108	What Does Sigmoidoscopy Really Miss?. American Journal of Gastroenterology, 2003, 98, 2326-2327.	0.2	2

#	ARTICLE	IF	CITATIONS
109	Influence of Varying Quantitative Fecal Immunochemical Test Positivity Thresholds on Colorectal Cancer Detection. <i>Annals of Internal Medicine</i> , 2019, 170, 736.	2.0	2
110	Long-Term Drug Treatment of GERD. <i>Disease Management and Health Outcomes</i> , 2004, 12, 399-407.	0.3	1
111	The Best Laid Plans: Adaptation is an Essential Part of Going From Efficacy Research to Program Implementation. <i>Gastroenterology</i> , 2017, 152, 693-694.	0.6	1
112	In simulation modelling, there are multiple ways to effectively screen for colorectal cancer. <i>Evidence-Based Medicine</i> , 2017, 22, 59-59.	0.6	0
113	Simplifying ADR Reporting: A Worthy Goal, but the Devil is in the Details. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1793-1795.	2.4	0